DK3093663T3 - Forudsigelse af risiko for større uønskede hjertehændelser - Google Patents

Forudsigelse af risiko for større uønskede hjertehændelser Download PDF

Info

Publication number
DK3093663T3
DK3093663T3 DK16166093.1T DK16166093T DK3093663T3 DK 3093663 T3 DK3093663 T3 DK 3093663T3 DK 16166093 T DK16166093 T DK 16166093T DK 3093663 T3 DK3093663 T3 DK 3093663T3
Authority
DK
Denmark
Prior art keywords
subject
time
macers
risk
level
Prior art date
Application number
DK16166093.1T
Other languages
English (en)
Inventor
James V Snider
Eugene R Heyman
Original Assignee
Critical Care Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Critical Care Diagnostics Inc filed Critical Critical Care Diagnostics Inc
Application granted granted Critical
Publication of DK3093663T3 publication Critical patent/DK3093663T3/da

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Claims (12)

  1. FORUDSIGELSE AF RISIKO FOR STØRRE UØNSKEDE HJERTEHÆNDELSER PATENTKRAV
    1. Fremgangsmåde til bestemmelse af risikoen for død for et individ med hjerteinsufficiens, hvilken fremgangsmåde omfatter: (a) bestemmelse af en første større uønskede hjertehændelser-risikoscore (MACERS) for et individ med hjerteinsufficiens baseret på, mindst delvis, forholdet mellem et andet niveau af opløseligt vækststimuleringsudtrykt gen 2 (ST2) hos individet på et andet tidspunkt (ST2 TI) og et første niveau af opløseligt ST2 hos individet på et første tidspunkt (ST2 TO), foruden en vægtet naturlig logaritme for et niveau af N-terminal pro-BNP (NP) hos individet på det andet tidspunkt (NP TI) i henhold til følgende formel: første MACERS = (ST2 T1/ST2 TO + aln(NP TI), hvor α er en vægtningsfaktor; (b) bestemmelse af en anden MACERS for et individ baseret på, mindst delvis, forholdet mellem et tredje niveau af opløseligt ST2 hos individet på et tredje tidspunkt (ST2 T2) med ST2 TO, foruden en vægtet naturlig logaritme for et niveau af NP hos individet på det tredje tidspunkt (NP T2) i henhold til følgende formel: anden MACERS = (ST2 T2/ST2 TO + <xln(NP T2) hvor α er en vægtningsfaktor; (c) sammenligning af den anden MACERS med den første MACERS; og (d) bestemmelse af individets risiko for død baseret på sammenligningen af den anden MACERS med den første MACERS.
  2. 2. Fremgangsmåde ifølge krav 1, hvor (d) omfatter bestemmelse af, at et individ med hjerteinsufficiens og en høj anden MACERS sammenlignet med den første MACERS har en øjet risiko for død sammenlignet med et individ med hjerteinsufficiens og som ikke har en øjet anden MACERS sammenlignet med den første MACERS.
  3. 3. Fremgangsmåde ifølge krav 1, hvor (d) omfatter bestemmelse af, at et individ med hjerteinsufficiens og en lav anden MACERS sammenlignet med den første MACERS har en lav risiko for død sammenlignet med et individ med hjerteinsufficiens og som ikke har en lav anden MACERS sammenlignet med den første MACERS.
  4. 4. Fremgangsmåde ifølge krav 1, hvor vægtningsfaktoren α er ca. 0,33.
  5. 5. Fremgangsmåde ifølge krav 1, hvor det første tidspunkt er inden for 1-7 dage efter symptomernes start hos individet.
  6. 6. Fremgangsmåde ifølge krav 1, hvor det andet tidspunkt er 2-14 dage efter det første tidspunkt.
  7. 7. Fremgangsmåde ifølge krav 1, hvor individet har et BMI på 25-29.
  8. 8. Fremgangsmåde ifølge krav 1, hvor individet har et BMI på > 30.
  9. 9. Fremgangsmåde ifølge krav 1, hvor individet har nyreinsufficiens.
  10. 10. Fremgangsmåde ifølge krav 1, hvor fremgangsmåden endvidere omfatter: udførelse af en immunanalyse for at bestemme det første niveau af opløseligt ST2 i en biologisk prøve, der erholdes af individet på det første tidspunkt (ST2 TO); udførelse af en immunanalyse for at bestemme det andet niveau af opløseligt ST2 i en biologisk prøve, der erholdes af individet på det andet tidspunkt (ST2 TI); udførelse af en immunanalyse for at bestemme det tredje niveau af opløseligt ST2 i en biologisk prøve, der erholdes af individet på det tredje tidspunkt (ST2 T2); udførelse af en immunanalyse for at bestemme det andet niveau af NP i en biologisk prøve, der erholdes af individet på det andet tidspunkt (NP TI); og udførelse af en immunanalyse for at bestemme det tredje niveau af NP i en biologisk prøve, der erholdes af individet på det tredje tidspunkt (NP T2).
  11. 11. Fremgangsmåde ifølge krav 1, hvor de biologiske prøver, der erholdes af individet vid det første tidspunkt, det andet tidspunkt og det tredje tidspunkt omfatter serum, blod eller plasma.
  12. 12. Fremgangsmåde ifølge krav 1, hvor de biologiske prøver, der erholdes af individet vid det første tidspunkt, det andet tidspunkt og det tredje tidspunkt omfatter serum.
DK16166093.1T 2008-04-18 2009-04-17 Forudsigelse af risiko for større uønskede hjertehændelser DK3093663T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4615808P 2008-04-18 2008-04-18
EP14177846.4A EP2827152B1 (en) 2008-04-18 2009-04-17 Predicting risk of major adverse cardiac events

Publications (1)

Publication Number Publication Date
DK3093663T3 true DK3093663T3 (da) 2018-09-24

Family

ID=41199760

Family Applications (4)

Application Number Title Priority Date Filing Date
DK14177846.4T DK2827152T3 (da) 2008-04-18 2009-04-17 Forudsigelse af risiko for større uønskede hjertehændelser
DK16166093.1T DK3093663T3 (da) 2008-04-18 2009-04-17 Forudsigelse af risiko for større uønskede hjertehændelser
DK13179055.2T DK2660599T3 (da) 2008-04-18 2009-04-17 Forudsigelse af risiko for større uønskede hjertehændelser
DK09731842.2T DK2269063T3 (da) 2008-04-18 2009-04-17 Forudsigelse af risiko for større uønskede hjertehændelser

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK14177846.4T DK2827152T3 (da) 2008-04-18 2009-04-17 Forudsigelse af risiko for større uønskede hjertehændelser

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK13179055.2T DK2660599T3 (da) 2008-04-18 2009-04-17 Forudsigelse af risiko for større uønskede hjertehændelser
DK09731842.2T DK2269063T3 (da) 2008-04-18 2009-04-17 Forudsigelse af risiko for større uønskede hjertehændelser

Country Status (14)

Country Link
US (5) US8090562B2 (da)
EP (5) EP3093663B1 (da)
JP (6) JP5526122B2 (da)
AU (3) AU2009236109B2 (da)
CA (1) CA2720674A1 (da)
DK (4) DK2827152T3 (da)
ES (4) ES2590213T3 (da)
HK (3) HK1185658A1 (da)
HR (2) HRP20131100T1 (da)
HU (2) HUE029880T2 (da)
PL (4) PL3093663T3 (da)
PT (4) PT2660599E (da)
SI (4) SI3093663T1 (da)
WO (1) WO2009129454A2 (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7432060B2 (en) 2000-11-09 2008-10-07 The Brigham And Women's Hospital, Inc. Methods for diagnosis of cardiovascular disease
HUE039881T2 (hu) 2002-05-09 2019-02-28 Brigham & Womens Hospital Inc 1L1RL-1, mint egy kardiovaszkuláris betegség-marker
AU2007244927B2 (en) 2006-04-24 2012-01-12 Critical Care Diagnostics, Inc. Predicting mortality and detecting severe disease
ATE517341T1 (de) * 2006-04-27 2011-08-15 Critical Care Diagnostics Inc Interleukin-33 (il-33) zur diagnose und vorhersage von herz-gefäss-erkrankungen
EP2021796B1 (en) 2006-05-01 2012-02-08 Critical Care Diagnostics, Inc. Diagnosis of cardiovascular disease
HUE025058T2 (en) * 2006-05-02 2016-01-28 Critical Care Diagnostics Inc Differential diagnosis of pulmonary and cardiovascular disease
US9968266B2 (en) 2006-12-27 2018-05-15 Cardiac Pacemakers, Inc. Risk stratification based heart failure detection algorithm
SI3093663T1 (sl) 2008-04-18 2018-10-30 Critical Care Diagnostics, Inc. Napovedovanje tveganja večjih neželenih srčno-žilnih dogodkov
CN107085114B (zh) * 2008-10-07 2021-05-25 B.R.A.H.M.S有限公司 用于预测初次不利事件的生物标志物
US9561006B2 (en) * 2008-10-15 2017-02-07 The United States Of America As Represented By The Secretary Of The Navy Bayesian modeling of pre-transplant variables accurately predicts kidney graft survival
US8417541B1 (en) * 2009-08-27 2013-04-09 Cerner Innovation, Inc. Multi-stage model for predicting probabilities of mortality in adult critically ill patients
EP2480129B1 (en) * 2009-09-25 2019-11-06 Volcano Corporation Device for determining the likelihood of a patient having a clinically silent event based on ascertained physiological parameters
CN103154027B (zh) 2010-04-09 2016-06-29 重症监护诊断股份有限公司 可溶性人st-2抗体和分析法
US10943676B2 (en) 2010-06-08 2021-03-09 Cerner Innovation, Inc. Healthcare information technology system for predicting or preventing readmissions
WO2012141844A2 (en) 2011-03-17 2012-10-18 Critical Care Diagnostics, Inc. Methods predicting risk of an adverse clinical outcome
CA2842072A1 (en) 2011-07-18 2013-01-24 James V. Snider Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy
EP2637023A1 (en) * 2012-03-08 2013-09-11 B.R.A.H.M.S GmbH Prediction of outcome in patients with chronic obstructive pulmonary disease
CN104507383B (zh) * 2012-05-18 2018-08-28 重症监护诊断股份有限公司 用于治疗或预报室性快速性心律失常事件风险的方法
CN102830234A (zh) * 2012-08-10 2012-12-19 杭州华得森生物技术有限公司 一种检测人心力衰竭新型标志物st2的快速诊断试剂盒
SG11201501200XA (en) 2012-08-16 2015-04-29 Critical Care Diagnostics Inc Methods for predicting risk of developing hypertension
SG11201501271TA (en) * 2012-08-21 2015-03-30 Critical Care Diagnostics Inc Multimarker risk stratification
RU2510505C1 (ru) * 2012-11-15 2014-03-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Тверская государственная медицинская академия" Министерства здравоохранения Российской Федерации Способ определения вероятности выраженной сердечной недостаточности в клинической картине инфаркта миокарда
GB201310290D0 (en) * 2013-06-10 2013-07-24 Univ Manchester Method for determining a probability of a major adverse cardiac event (MACE)
CA2935958A1 (en) * 2014-01-10 2015-07-16 Critical Care Diagnostics, Inc. Methods and systems for determining risk of heart failure
CA2961340C (en) 2014-09-26 2023-10-17 Somalogic, Inc. Cardiovascular risk event prediction and uses thereof
US10324089B2 (en) 2014-12-11 2019-06-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US10079073B2 (en) 2014-12-11 2018-09-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US20160256064A1 (en) * 2015-03-02 2016-09-08 Edward Harvey Estes, JR. Method and device to predict adverse cardiovascular events and mortality from an electrocardiogram-based validated risk score
CN109152529B (zh) * 2016-04-01 2021-10-22 心脏起搏器股份公司 多疾病患者管理
AT518560B1 (de) * 2016-04-18 2018-01-15 Trumpf Maschinen Austria Gmbh & Co Kg Biegebalken für eine Schwenkbiegemaschine
EP3614908A1 (en) 2017-04-29 2020-03-04 Cardiac Pacemakers, Inc. Heart failure event rate assessment
JP7057995B2 (ja) 2017-10-03 2022-04-21 株式会社国際電気通信基礎技術研究所 哺乳動物におけるうつ病の病態プロファイルを検出するバイオマーカーとその利用
US20200074313A1 (en) * 2018-08-29 2020-03-05 Koninklijke Philips N.V. Determining features to be included in a risk assessment instrument
JP7043374B2 (ja) 2018-09-18 2022-03-29 株式会社日立製作所 多機能神経フィードバックシステム及び多機能神経フィードバック方法
US11446009B2 (en) 2018-12-11 2022-09-20 Eko.Ai Pte. Ltd. Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images
US11931207B2 (en) 2018-12-11 2024-03-19 Eko.Ai Pte. Ltd. Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device
US11551817B2 (en) 2020-01-14 2023-01-10 International Business Machines Corporation Assessing unreliability of clinical risk prediction
CN117099000A (zh) * 2021-03-08 2023-11-21 赛诺菲 心血管疾病

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
US5206140A (en) 1988-06-24 1993-04-27 Research Corporation Technologies, Inc. Assay for soluble crosslinked fibrin polymers
US5217899A (en) 1990-08-24 1993-06-08 The General Hospital Corporation Cell stretching apparatus
JP2665850B2 (ja) 1991-11-14 1997-10-22 塩野義製薬株式会社 ｈＢＮＰのＣ端を認識するモノクロ−ナル抗体
GB9211686D0 (en) 1992-06-03 1992-07-15 Medisinsk Innovation A S Chemical compounds
JP2732005B2 (ja) 1992-12-14 1998-03-25 眞一 富永 ヒトｓｔ２をコードするｄｎａ、該ｄｎａの発現産物、該ｄｎａを発現させることによる発現産物の製造方法
JPH0731479A (ja) 1993-02-23 1995-02-03 Shinichi Tominaga マウスｓｔ２ｌをコードするｄｎａ、該ｄｎａの発現産物、該ｄｎａを発現させることによる発現産物の製造方法
US6066322A (en) 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
CA2263832A1 (en) 1996-08-23 1998-02-26 Human Genome Sciences, Inc. T1 receptor-like ligand ii
WO1998038311A1 (en) 1997-02-28 1998-09-03 Human Genome Sciences, Inc. T1/st2-receptor ligand iii
DE19711932A1 (de) 1997-03-21 1998-09-24 Anne Katrin Dr Werenskiold In vitro-Verfahren zum Prognostizieren des Krankheitsverlaufs von Patienten mit Mammakarzinom und/oder zum Diagnostizieren eines Mammakarzinoms
EP2305236A1 (en) 1997-04-02 2011-04-06 The Brigham And Women's Hospital, Inc. Means of Ascertaining an Individual's Risk Profile for Atherosclerotic Disease
JP5264026B2 (ja) 1997-06-10 2013-08-14 エルパス・インコーポレイテッド 心疾患の早期発見のための方法
AU731858B2 (en) 1997-09-11 2001-04-05 Shionogi & Co., Ltd. Immunoassay for BNP
GB9727172D0 (en) 1997-12-24 1998-02-25 Univ Glasgow Reagents specific for st2l and uses therefor
US6309888B1 (en) 1998-09-04 2001-10-30 Leuven Research & Development Vzw Detection and determination of the stages of coronary artery disease
GB9827348D0 (en) * 1998-12-12 1999-02-03 Univ Leicester Natriuretic peptide
EP1140137A2 (en) 1998-12-18 2001-10-10 Scios Inc. Method for detection and use of differentially expressed genes in disease states
AU5309600A (en) 1999-06-02 2000-12-18 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of immune disorders
FR2795823B1 (fr) 1999-07-01 2001-11-23 Inst Nat Sante Rech Med Methodes et kits pour le diagnostic ou le suivi d'une pathologie synoviale ou osteoarticulaire comprenant l'utilisation d'un marqueur specifique de la degradation du tissu synovial
CA2383252A1 (en) 1999-08-24 2001-03-01 Medicure International Inc. Treatment of cardiovascular related pathologies
US6323334B1 (en) 1999-09-24 2001-11-27 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding a 103 gene product and uses therefor
WO2001070817A1 (fr) 2000-03-21 2001-09-27 Medical & Biological Laboratories Co., Ltd. Anticorps monoclonal et methode et kit d'immunodosage de st2 humaine soluble l'utilisant
FR2807170B1 (fr) 2000-03-30 2002-06-28 Sipal Charniere elastique a frottement reduit
US20020115081A1 (en) 2000-08-22 2002-08-22 Lee Richard T. Diagnosis and treatment of cardiovascular conditions
US7432060B2 (en) 2000-11-09 2008-10-07 The Brigham And Women's Hospital, Inc. Methods for diagnosis of cardiovascular disease
US6537221B2 (en) 2000-12-07 2003-03-25 Koninklijke Philips Electronics, N.V. Strain rate analysis in ultrasonic diagnostic images
FI20010019A (fi) 2001-01-05 2002-07-06 Biohit Oyj Menetelmä atrofisen diagnostisoimiseksi
US20040253637A1 (en) 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
US7713705B2 (en) 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
JP3806694B2 (ja) 2001-05-04 2006-08-09 バイオサイト インコーポレイテッド 急性冠状動脈症候群の診断マーカーおよびその使用方法
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
WO2003022987A2 (en) 2001-07-26 2003-03-20 Eos Biotechnology, Inc. Methods of diagnosis of hepatitis c infection, compositions and methods of screening for modulators of hepatitis c infection
US6810284B1 (en) 2001-11-21 2004-10-26 Pacesetter, Inc. Implantable cardiac stimulation system and method for monitoring diastolic function
HUE039881T2 (hu) 2002-05-09 2019-02-28 Brigham & Womens Hospital Inc 1L1RL-1, mint egy kardiovaszkuláris betegség-marker
WO2003100000A2 (en) 2002-05-24 2003-12-04 Tularik Inc. Amplification and overexpression of oncogenes
US8263325B2 (en) 2002-11-15 2012-09-11 Ottawa Heart Institute Research Corporation Predicting, detecting and monitoring treatment of cardiomyopathies and myocarditis
JP2006507510A (ja) * 2002-11-21 2006-03-02 インバーネス・メデイカル・スウイツツアーランド・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング 組織低酸素症の体液マーカー
US20070042978A1 (en) 2002-12-19 2007-02-22 Jean-Philippe Girard Nf-hev compositions and methods of use
US20040133079A1 (en) 2003-01-02 2004-07-08 Mazar Scott Thomas System and method for predicting patient health within a patient management system
US20040220155A1 (en) 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
US20050123451A1 (en) 2003-10-31 2005-06-09 Hiroshi Nomura System and apparatus for body fluid analysis using surface-textured optical materials
WO2005056837A2 (en) 2003-11-26 2005-06-23 Applera Corporation Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof
WO2005055810A2 (en) 2003-12-05 2005-06-23 The Cleveland Clinic Foundation Risk markers for cardiovascular disease
US20050196817A1 (en) 2004-01-20 2005-09-08 Molecular Staging Inc. Biomarkers for sepsis
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
JP2005291899A (ja) 2004-03-31 2005-10-20 Akira Matsumori 心疾患の検査法
WO2006066095A1 (en) 2004-12-17 2006-06-22 Clearwater Systems Corporation Method and apparatus for treating fluids
CA2595794A1 (en) 2005-01-24 2006-07-27 F. Hoffmann-La Roche Ag The use of cardiac hormones for assessing a cardiovascular risk with respect to the administration of anti-inflammatory drugs
EP1731910A1 (en) 2005-06-07 2006-12-13 F. Hoffmann-La Roche Ag Use of NT-proANP and NT-proBNP for diagnosing cardiac diseases
US20070021977A1 (en) 2005-07-19 2007-01-25 Witt Biomedical Corporation Automated system for capturing and archiving information to verify medical necessity of performing medical procedure
JP4820192B2 (ja) 2006-03-17 2011-11-24 一般財団法人化学及血清療法研究所 急性冠症候群でのａｄａｍｔｓ１３の測定と利用
AU2007244927B2 (en) * 2006-04-24 2012-01-12 Critical Care Diagnostics, Inc. Predicting mortality and detecting severe disease
ATE517341T1 (de) 2006-04-27 2011-08-15 Critical Care Diagnostics Inc Interleukin-33 (il-33) zur diagnose und vorhersage von herz-gefäss-erkrankungen
EP2021796B1 (en) 2006-05-01 2012-02-08 Critical Care Diagnostics, Inc. Diagnosis of cardiovascular disease
HUE025058T2 (en) 2006-05-02 2016-01-28 Critical Care Diagnostics Inc Differential diagnosis of pulmonary and cardiovascular disease
US8147817B2 (en) 2006-05-04 2012-04-03 The Brigham And Women's Hospital, Inc. IL-33 in the treatment and diagnosis of diseases and disorders
WO2007146229A2 (en) * 2006-06-07 2007-12-21 Tethys Bioscience, Inc. Markers associated with arteriovascular events and methods of use thereof
RU2312591C1 (ru) 2006-06-14 2007-12-20 Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная медицинская академия им. И.И. Мечникова Федерального агентства по здравоохранению и социальному развитию" Способ прогнозирования развития риска внезапной смерти у больных с лево- и правожелудочковой экстрасистолией
US20080233191A1 (en) 2007-03-22 2008-09-25 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
JP2010526555A (ja) 2007-05-11 2010-08-05 タフツ・メディカル・センター 加齢関連黄斑変性と関係するポリヌクレオチド及び患者のリスクを評価する方法
GB0713404D0 (en) 2007-07-11 2007-08-22 Integra Sp Ipr Ltd Altio graph
WO2009040133A1 (en) 2007-09-26 2009-04-02 Universitätsklinikum Heidelberg Osteopontin as novel prognostic biomarker for heart failure
FR2923029B1 (fr) 2007-10-26 2009-11-20 Minima Lunettes de type sans entourage a branches filaires
SI3093663T1 (sl) 2008-04-18 2018-10-30 Critical Care Diagnostics, Inc. Napovedovanje tveganja večjih neželenih srčno-žilnih dogodkov
WO2010025393A2 (en) * 2008-08-28 2010-03-04 The Regents Of The University Of California Protein biomarkers and methods for diagnosing kawasaki disease
EP2347266B9 (en) 2008-11-11 2014-02-12 B.R.A.H.M.S GmbH Prognosis and risk assessment in patients suffering from heart failure by determining the level of adm
JP5728488B2 (ja) 2009-11-13 2015-06-03 ビージー メディシン， インコーポレイテッド 心筋梗塞のリスクファクターおよび予測
US8258456B2 (en) 2009-11-27 2012-09-04 Himax Imaging, Inc. Image sensor
CN103154027B (zh) 2010-04-09 2016-06-29 重症监护诊断股份有限公司 可溶性人st-2抗体和分析法
CN103328976B (zh) 2010-11-01 2016-08-10 B.R.A.H.M.S有限公司 具有非特定主诉的患者的预后和风险评估
RU2452394C1 (ru) 2010-11-09 2012-06-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования Ульяновский государственный университет Способ прогнозирования риска смерти больных хронической сердечной недостаточностью
WO2012141844A2 (en) 2011-03-17 2012-10-18 Critical Care Diagnostics, Inc. Methods predicting risk of an adverse clinical outcome
US8615387B2 (en) * 2011-04-07 2013-12-24 Invensys Systems, Inc. Dynamic simulation of fluid filled vessels
CA2842072A1 (en) 2011-07-18 2013-01-24 James V. Snider Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy
CN104507383B (zh) 2012-05-18 2018-08-28 重症监护诊断股份有限公司 用于治疗或预报室性快速性心律失常事件风险的方法
SG11201501200XA (en) * 2012-08-16 2015-04-29 Critical Care Diagnostics Inc Methods for predicting risk of developing hypertension
SG11201501271TA (en) * 2012-08-21 2015-03-30 Critical Care Diagnostics Inc Multimarker risk stratification
US9665593B2 (en) * 2013-03-28 2017-05-30 International Business Machines Corporation Dynamically synching elements in file
JP6178687B2 (ja) 2013-09-27 2017-08-09 富士機械工業株式会社 グラビア塗工装置
CA2935958A1 (en) 2014-01-10 2015-07-16 Critical Care Diagnostics, Inc. Methods and systems for determining risk of heart failure
USD770057S1 (en) 2014-04-14 2016-10-25 Critical Care Diagnostics, Inc. Blood test kit
US9934249B2 (en) 2014-06-03 2018-04-03 Conduent Business Machines Services, Llc Systems and methods for context-aware and personalized access to visualizations of road events
USD800332S1 (en) 2014-09-23 2017-10-17 Critical Care Diagnostics, Inc. Blood test kit
USD800333S1 (en) 2014-09-23 2017-10-17 Critical Care Diagnostics, Inc. Blood test kit
US10324089B2 (en) 2014-12-11 2019-06-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US10079073B2 (en) 2014-12-11 2018-09-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker

Also Published As

Publication number Publication date
EP2827152B1 (en) 2016-06-08
PL2827152T3 (pl) 2016-12-30
US20180233229A1 (en) 2018-08-16
PT2660599E (pt) 2014-11-28
AU2016200697A1 (en) 2016-02-25
EP2827152A1 (en) 2015-01-21
JP6200975B2 (ja) 2017-09-20
JP2016048272A (ja) 2016-04-07
HUE039963T2 (hu) 2019-02-28
ES2443125T3 (es) 2014-02-17
US11170896B2 (en) 2021-11-09
ES2687401T3 (es) 2018-10-25
US20090264779A1 (en) 2009-10-22
SI2269063T1 (sl) 2014-01-31
EP2269063A4 (en) 2011-05-04
JP2011520098A (ja) 2011-07-14
US8090562B2 (en) 2012-01-03
EP3093663A1 (en) 2016-11-16
HRP20131100T1 (hr) 2014-01-31
EP2660599B1 (en) 2014-09-10
JP2014178322A (ja) 2014-09-25
HUE029880T2 (en) 2017-04-28
AU2016200697B2 (en) 2018-01-04
DK2660599T3 (da) 2014-12-08
AU2009236109A1 (en) 2009-10-22
JP2021039108A (ja) 2021-03-11
US20150081224A1 (en) 2015-03-19
HK1152750A1 (en) 2012-03-09
JP5873521B2 (ja) 2016-03-01
JP2017203784A (ja) 2017-11-16
JP6788050B2 (ja) 2020-11-18
SI2660599T1 (sl) 2014-12-31
ES2525029T3 (es) 2014-12-16
HK1206419A1 (en) 2016-01-08
EP3093663B1 (en) 2018-06-13
PL2269063T3 (pl) 2014-04-30
US20130244236A1 (en) 2013-09-19
JP6484679B2 (ja) 2019-03-13
JP2019105645A (ja) 2019-06-27
WO2009129454A3 (en) 2010-01-28
CA2720674A1 (en) 2009-10-22
PL3093663T3 (pl) 2018-11-30
EP3378955A1 (en) 2018-09-26
EP2269063B1 (en) 2013-08-21
DK2827152T3 (da) 2016-09-12
PT2827152T (pt) 2016-09-13
AU2009236109B2 (en) 2015-11-05
WO2009129454A2 (en) 2009-10-22
US9886553B2 (en) 2018-02-06
US20120065897A1 (en) 2012-03-15
HK1185658A1 (en) 2014-02-21
PT3093663T (pt) 2018-10-19
SI3093663T1 (sl) 2018-10-30
SI2827152T1 (sl) 2016-10-28
JP5526122B2 (ja) 2014-06-18
DK2269063T3 (da) 2013-12-02
PT2269063E (pt) 2013-11-27
PL2660599T3 (pl) 2015-03-31
AU2018202350A1 (en) 2018-04-26
HRP20141056T1 (hr) 2015-01-02
US9965593B2 (en) 2018-05-08
EP2269063A2 (en) 2011-01-05
ES2590213T3 (es) 2016-11-18
EP2660599A1 (en) 2013-11-06

Similar Documents

Publication Publication Date Title
US11170896B2 (en) Predicting risk of major adverse cardiac events
US11016103B2 (en) Predicting mortality and detecting severe disease